AbbVie
ABBV
3,007 hedge funds and large institutions have $187B invested in AbbVie in 2022 Q2 according to their latest regulatory filings, with 131 funds opening new positions, 1,159 increasing their positions, 1,322 reducing their positions, and 136 closing their positions.
19% more call options, than puts
Call options by funds: $3B | Put options by funds: $2.51B
11% more funds holding in top 10
Funds holding in top 10: 297 → 331 (+34)
0.75% more ownership
Funds ownership: 68.2% → 68.96% (+0.75%)
4% less first-time investments, than exits
New positions opened: 131 | Existing positions closed: 136
4% less capital invested
Capital invested by funds: $195B → $187B (-$8.46B)
1% less funds holding
Funds holding: 3,052 → 3,007 (-45)
12% less repeat investments, than reductions
Existing positions increased: 1,159 | Existing positions reduced: 1,322
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital International Investors
Los Angeles,
California
|
+$1.93B |
| 2 |
Capital Research Global Investors
Los Angeles,
California
|
+$1.41B |
| 3 |
Morgan Stanley
New York
|
+$1.1B |
| 4 |
BlackRock
New York
|
+$775M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$468M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$905M |
| 2 |
PI
Putnam Investments
Boston,
Massachusetts
|
-$377M |
| 3 |
Two Sigma Advisers
New York
|
-$283M |
| 4 |
Nuveen
Charlotte,
North Carolina
|
-$260M |
| 5 |
Franklin Resources
San Mateo,
California
|
-$206M |
ABBV Hedge Fund Activity: Q2 2022 in Review
3,007 of the 5,960 institutional investors tracked by Wall St. Rank reported a position in AbbVie (ABBV) for Q2 2022, worth a combined $187B — down 4.3% from $195B a quarter earlier.
Sellers outnumbered buyers: 136 funds closed out of ABBV and 131 opened new positions — a net loss of 5 holders — while 1,322 trimmed existing stakes and 1,159 added.
The largest buyer was Capital International Investors, adding an estimated $1.93B. The largest seller was T. Rowe Price Associates, cutting an estimated $905M.
- 3,007 institutional investors held AbbVie (ABBV) as of Q2 2022, down from 3,052 in Q1 2022.
- Funds reported $187B of AbbVie stock for Q2 2022, down 4.3% quarter-over-quarter.
- 131 funds opened new AbbVie positions in Q2 2022 and 136 closed out, a net change of -5 holders.
- The largest AbbVie buyer in Q2 2022 was Capital International Investors, an estimated $1.93B added.
- The largest AbbVie seller in Q2 2022 was T. Rowe Price Associates, an estimated $905M sold.
Based on aggregated 13F filings for Q2 2022.